Histology
Non-Small Cell Adenocarcinoma
CI-CAN-00003439Explore in graph →
53 active trials127 evidence items
- NCIt
- C27745
Loading cancer entity…
Loading cancer entity…
Histology
CI-CAN-00003439Explore in graph →
Clinical trials
236 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (29)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02788058 | A Study of Hypofractionated Radiotherapy for Limited Metastatic NSCLC Harboring Sensitizing EGFR Mutations After First Line TKI Therapy | unknown | Phase 2 | 76 | First People's Hospital of HangzhouOTHER | 0 | Jun 2, 2016 | clinicaltrials |
| NCT02738684 | A Study to Predict Gefitinib' s Efficacy for Lung Cancer by Plasma Free Nucleic Acids EGFR Gene Mutation Test | unknown | — | 100 | Southwest Hospital, ChinaOTHER | 0 | Apr 14, 2016 |
| NCT01819428 | NOV120101 (Poziotinib) for 1st Line Monotherapy in Patients With Lung Adenocarcinoma | terminated | Phase 2 | 22 | National OncoVentureOTHER | 1 | Mar 1, 2016 | clinicaltrials |
| NCT02691871 | Apatinib Plus Docetaxel as 2nd Line Treatment in Patients With Advanced Lung Adenocarcinoma Harboring Wild-type EGFR | unknown | Phase 1 | 20 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 0 | Feb 25, 2016 | clinicaltrials |
| NCT02493582 | The Study of Apatinib Plus CIK as the Third Line Therapy for Advanced Lung Adenocarcinoma Patients With Wild-Type EGFR | active not recruiting | Phase 2 | 400 | The First People's Hospital of ChangzhouOTHER | 0 | Feb 5, 2016 | clinicaltrials |
| NCT00368992 | S0536: Cetuximab, Paclitaxel, Carboplatin, and Bevacizumab in Treating Patients With Advanced Non-Small Cell Lung Cancer | completed | Phase 2 | 110 | National Cancer Institute (NCI)NIH | 1 | Sep 14, 2015 | clinicaltrials |
| NCT02132143 | Comparative Study of Chemoradiation and Sequential Chemoradiation About Lung Adenocarcinoma Patients With Postoperative in pN2 | unknown | N/A | 60 | Hui LinOTHER | 1 | May 6, 2015 | clinicaltrials |
| NCT00716456 | Cetuximab in Patients With Lung Adenocarcinoma Receiving Erlotinib That Have Developed "Acquired Resistance" to Erlotinib | completed | Phase 1 / Phase 2 | 21 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 30, 2015 | clinicaltrials |
| NCT02399566 | Clinical Trial of Erlotinib and Pemetrexed for Maintenance Treatment in Lung Adenocarcinoma | unknown | Phase 4 | 300 | Hunan Province Tumor HospitalOTHER | 0 | Mar 26, 2015 | clinicaltrials |
| NCT02059967 | Phase I IGART Study Using Active Breathing Control and Simultaneous Boost for Patients With NSCLC | withdrawn | Phase 1 | 0 | Virginia Commonwealth UniversityOTHER | 0 | Mar 19, 2015 | clinicaltrials |
| NCT00511485 | Study of Vintafolide (MK-8109, EC145) in Participants With Progressive Adenocarcinoma of the Lung (MK-8109-008, EC-FV-03) | completed | Phase 2 | 43 | EndocyteINDUSTRY | 0 | Feb 27, 2015 | clinicaltrials |
| NCT00384826 | Therapeutic Strategy in Advanced Bronchioloalveolar Carcinoma | completed | Phase 2 | 133 | Intergroupe Francophone de Cancerologie ThoraciqueOTHER | 1 | Feb 16, 2015 | clinicaltrials |
| NCT01578668 | Erlotinib Plus Pemetrexed to Treat Lung Adenocarcinoma With Brain Metastases | completed | Phase 2 | 69 | Guangzhou Medical UniversityOTHER | 1 | Jan 26, 2015 | clinicaltrials |
| NCT00049543 | Gefitinib in Treating Patients With Stage IB, II, or IIIA Non-small Cell Lung Cancer That Was Completely Removed by Surgery | completed | Phase 3 | 503 | National Cancer Institute (NCI)NIH | 1 | Jan 1, 2015 | clinicaltrials |
| NCT02288026 | Comparison of Different Types of Surgery in Treating Patients With Early-stage Non-small Cell Lung Cancer | unknown | — | 630 | Capital Medical UniversityOTHER | 1 | Nov 11, 2014 | clinicaltrials |
| NCT02239432 | Telomere Biology in Early Adenocarcinoma of the Lung | unknown | — | 100 | Meir Medical CenterOTHER | 1 | Sep 12, 2014 | clinicaltrials |
| NCT00118144 | Bortezomib in Treating Patients With Stage IIIB or Stage IV Lung Cancer | completed | Phase 2 | 42 | National Cancer Institute (NCI)NIH | 1 | Aug 21, 2014 | clinicaltrials |
| NCT01668823 | Photodynamic Therapy in Treating Patients With Lung Cancer | completed | Phase 1 | 17 | Roswell Park Cancer InstituteOTHER | 1 | Jul 31, 2014 | clinicaltrials |
| NCT00369551 | Bevacizumab, Paclitaxel, Carboplatin, and Radiation Therapy to the Chest in Treating Patients With Locally Advanced Non-Small Cell Lung Cancer | terminated | Phase 1 | 36 | National Cancer Institute (NCI)NIH | 1 | Mar 6, 2014 | clinicaltrials |
| NCT02011997 | Comparison of cVATS Segmentectomy Versus Lobectomy for Lung Adenocarcinoma in Situ and With Microinvasion(cVATS) | unknown | Phase 3 | 500 | The First Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Dec 16, 2013 | clinicaltrials |
| NCT01561456 | Study of AXL1717 Compared to Docetaxel to Treat Squamous Cell Carcinoma or Adenocarcinoma of the Lung | completed | Phase 2 | 100 | Axelar ABINDUSTRY | 5 | Dec 5, 2013 | clinicaltrials |
| NCT01942629 | Prognostic Value of the Marker P63 in Adenocarcinoma of Lung, Breast, and Pancreas | unknown | — | 300 | Rambam Health Care CampusOTHER | 0 | Sep 16, 2013 | clinicaltrials |
| NCT00002852 | Surgery With or Without Chemotherapy in Treating Patients With Stage I Non-small Cell Lung Cancer | completed | Phase 3 | 500 | National Cancer Institute (NCI)NIH | 1 | Jul 3, 2013 | clinicaltrials |
| NCT00040794 | Combination Chemotherapy, Radiation Therapy, and Gefitinib in Treating Patients With Stage III Non-Small Cell Lung Cancer | completed | Phase 2 | 144 | National Cancer Institute (NCI)NIH | 1 | Jun 5, 2013 | clinicaltrials |
| NCT00118183 | Docetaxel With Either Cetuximab or Bortezomib as First-Line Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer | completed | Phase 2 | 62 | National Cancer Institute (NCI)NIH | 1 | Jun 4, 2013 | clinicaltrials |
| NCT00029003 | Gefitinib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer | completed | Phase 2 | 90 | National Cancer Institute (NCI)NIH | 1 | Feb 28, 2013 | clinicaltrials |
| NCT00087412 | S0341: Erlotinib in Treating Patients With Advanced Primary Non-Small Cell Lung Cancer | completed | Phase 2 | 65 | National Cancer Institute (NCI)NIH | 1 | Feb 28, 2013 | clinicaltrials |
| NCT00020709 | Combination Chemotherapy and Radiation Therapy With or Without Gefitinib in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery | completed | Phase 3 | 840 | National Cancer Institute (NCI)NIH | 1 | Feb 27, 2013 | clinicaltrials |
| NCT00021060 | Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Advanced, Metastatic, or Recurrent Non-Small Cell Lung Cancer | completed | Phase 2 / Phase 3 | 842 | National Cancer Institute (NCI)NIH | 1 | Feb 27, 2013 | clinicaltrials |
| NCT00042835 | Erlotinib and Radiation Therapy Plus Combination Chemotherapy in Treating Patients With Inoperable Stage III Non-Small Cell Lung Cancer | terminated | Phase 1 | 48 | National Cancer Institute (NCI)NIH | 1 | Feb 1, 2013 | clinicaltrials |
| NCT00005838 | Combination Chemotherapy Plus Radiation Therapy With or Without AE-941 in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed By Surgery | completed | Phase 3 | 756 | National Cancer Institute (NCI)NIH | 1 | Jan 23, 2013 | clinicaltrials |
| NCT01482585 | Study of Early-stage Lung Adenocarcinoma for Early Detection and Effective Treatment Strategy | unknown | — | 200 | Samsung Medical CenterOTHER | 1 | Nov 30, 2011 | clinicaltrials |
| NCT00117351 | VELCADE in Previously Treated Patients With Stage IIIB and IV Bronchioloalveolar Carcinoma (BAC) and Adenocarcinoma With BAC Features | terminated | Phase 2 | — | Millennium Pharmaceuticals, Inc.INDUSTRY | 1 | Feb 17, 2011 | clinicaltrials |
| NCT01249053 | Expression of Optic Atrophy Type 1 (OPA1) Protein in Lung Adenocarcinoma | unknown | — | 100 | China Medical University HospitalOTHER | 1 | Nov 29, 2010 | clinicaltrials |
| NCT01249066 | Expression of AMP-activated Protein Kinase (AMPK) Protein in Lung Adenocarcinoma | unknown | — | 100 | China Medical University HospitalOTHER | 1 | Nov 29, 2010 | clinicaltrials |
| NCT00339586 | First-Line EGFR-1 Tyrosine Kinase Inhibition in Patients With NSCLC With Mutant EGFR Gene | unknown | Phase 2 | 40 | Universitair Ziekenhuis BrusselOTHER | 1 | Jun 21, 2006 | clinicaltrials |
Data updated 22 days agoSource updated Jun 2, 2016source: clinicaltrials